drugset / Trial / NCT02225912

A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers

NCT02225912 ↗

Phase 4 Completed BioHealth Technologies Inc.
CrossoverTriple-blind

Summary

The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.

Timeline

Start
2005-02
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject PrevinC Unknown — Intranasal